MX2020007852A - Metodos para el tratamiento de la atrofia muscular espinal. - Google Patents

Metodos para el tratamiento de la atrofia muscular espinal.

Info

Publication number
MX2020007852A
MX2020007852A MX2020007852A MX2020007852A MX2020007852A MX 2020007852 A MX2020007852 A MX 2020007852A MX 2020007852 A MX2020007852 A MX 2020007852A MX 2020007852 A MX2020007852 A MX 2020007852A MX 2020007852 A MX2020007852 A MX 2020007852A
Authority
MX
Mexico
Prior art keywords
methods
muscular atrophy
spinal muscular
treating spinal
sma
Prior art date
Application number
MX2020007852A
Other languages
English (en)
Inventor
Wildon Farwell
John Staropoli
Guolin Zhao
Alexander Mccampbell
Christopher Cody Stebbins
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2020007852A publication Critical patent/MX2020007852A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Se presentan biomarcadores para, por ejemplo, diagnosticar y pronosticar la atrofia muscular espinal (AME), así como para identificar a los respondedores del tratamiento para la AME. También se proporcionan métodos para tratar individuos con AME.
MX2020007852A 2018-01-25 2019-01-25 Metodos para el tratamiento de la atrofia muscular espinal. MX2020007852A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862622027P 2018-01-25 2018-01-25
US201862684507P 2018-06-13 2018-06-13
US201862738134P 2018-09-28 2018-09-28
PCT/US2019/015185 WO2019147960A1 (en) 2018-01-25 2019-01-25 Methods of treating spinal muscular atrophy

Publications (1)

Publication Number Publication Date
MX2020007852A true MX2020007852A (es) 2021-01-29

Family

ID=65529774

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007852A MX2020007852A (es) 2018-01-25 2019-01-25 Metodos para el tratamiento de la atrofia muscular espinal.

Country Status (13)

Country Link
US (2) US11474113B2 (es)
EP (1) EP3743728A1 (es)
JP (2) JP7506606B2 (es)
KR (1) KR20200112906A (es)
CN (1) CN112567246A (es)
AU (1) AU2019211446A1 (es)
BR (1) BR112020015082A2 (es)
CL (1) CL2020001936A1 (es)
IL (1) IL276180A (es)
MA (1) MA51678A (es)
MX (1) MX2020007852A (es)
SG (1) SG11202006677XA (es)
WO (1) WO2019147960A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020007852A (es) 2018-01-25 2021-01-29 Biogen Ma Inc Metodos para el tratamiento de la atrofia muscular espinal.
CN115004350A (zh) 2019-06-11 2022-09-02 库力索法荷兰有限公司 利用光学系统特性的调整的分立组件装配体的位置误差补偿
PL3999643T3 (pl) 2019-07-19 2024-02-19 Biogen Ma Inc. Sposoby leczenia rdzeniowego zaniku mięśni i zapobiegania mu
CA3220428A1 (en) * 2021-06-08 2022-12-15 Alector Llc Methods of use of anti-sortilin antibodies
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US4582789A (en) 1984-03-21 1986-04-15 Cetus Corporation Process for labeling nucleic acids using psoralen derivatives
US4563417A (en) 1984-08-31 1986-01-07 Miles Laboratories, Inc. Nucleic acid hybridization assay employing antibodies to intercalation complexes
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
WO1992010588A1 (en) 1990-12-06 1992-06-25 Affymax Technologies N.V. Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides
US6027880A (en) 1995-08-02 2000-02-22 Affymetrix, Inc. Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
US6057100A (en) 1996-06-07 2000-05-02 Eos Biotechnology, Inc. Oligonucleotide arrays
AU2002247248B2 (en) 2001-03-02 2007-07-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education PCR method
EP1379545A2 (de) 2001-04-19 2004-01-14 Gesellschaft für biotechnologische Forschung mbH (GBF) Verfahren zur herstellung stabiler, regenerierbarer antikörper-arrays
US6812341B1 (en) 2001-05-11 2004-11-02 Ambion, Inc. High efficiency mRNA isolation methods and compositions
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
US7252976B2 (en) 2002-08-28 2007-08-07 Board Of Regents The University Of Texas System Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample
PL2548560T3 (pl) 2005-06-23 2015-11-30 Biogen Ma Inc Kompozycje i sposoby modulowania splicingu SMN2
CA2659376C (en) 2006-08-01 2014-10-14 Jasbir Singh 2,4-diaminoquinazolines for spinal muscular atrophy
US9765297B2 (en) 2007-04-13 2017-09-19 The Trustees Of Columbia University In The City Of New York Stem cell-based culture system for drug development
SG10202109219SA (en) 2009-05-02 2021-10-28 Genzyme Corp Gene therapy for neurodegenerative disorders
PT3449926T (pt) 2009-06-17 2019-11-12 Cold Spring Harbor Laboratory Composições e métodos de modulação de excisões de smn2 em um sujeito
US8465727B2 (en) 2009-10-06 2013-06-18 University of Pittsburgh—of the Commonwealth System of Higher Education Biomarkers for the diagnosis of ALS
US9926559B2 (en) 2013-01-09 2018-03-27 Biogen Ma Inc. Compositions and methods for modulation of SMN2 splicing in a subject
KR20220077933A (ko) 2014-04-01 2022-06-09 바이오젠 엠에이 인코포레이티드 Sod-1 발현을 조절하기 위한 조성물
US10024870B2 (en) 2014-04-02 2018-07-17 Wisconsin Alumni Research Foundation Therapeutic and diagnostic methods and compositions for neurodegenerative diseases
WO2015161170A2 (en) 2014-04-17 2015-10-22 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
BR112017004056A2 (pt) 2014-09-12 2017-12-05 Biogen Ma Inc composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
RU2018133288A (ru) * 2016-02-23 2020-03-24 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Комбинированные терапии для лечения спинальной мышечной атрофии
JP2019517516A (ja) 2016-06-03 2019-06-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｓｍａの新規な処置
WO2018218219A1 (en) * 2017-05-26 2018-11-29 University Of Miami Determining onset of amyotrophic lateral sclerosis
CN111479924B (zh) * 2017-10-16 2024-06-14 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
MX2020007852A (es) 2018-01-25 2021-01-29 Biogen Ma Inc Metodos para el tratamiento de la atrofia muscular espinal.
EA201992364A1 (ru) * 2018-04-02 2020-03-23 Кохерус Байосайенсис Инк. АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА
WO2020061355A2 (en) 2018-09-20 2020-03-26 Biogen Ma Inc. Serum neurofilament protein for guiding therapeutic intervention in multiple sclerosis
CA3121749A1 (en) 2018-12-06 2020-06-11 Biogen Ma Inc. Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis
TW202035694A (zh) 2018-12-14 2020-10-01 美商百健Ｍａ公司 用於治療及預防肌肉萎縮性脊髓側索硬化症之組合物及方法
EP3924739A1 (en) 2019-02-12 2021-12-22 Biogen MA Inc. Biomarkers of progressive multifocal leukoencephalopathy

Also Published As

Publication number Publication date
CL2020001936A1 (es) 2020-12-18
MA51678A (fr) 2020-12-02
KR20200112906A (ko) 2020-10-05
US11474113B2 (en) 2022-10-18
EP3743728A1 (en) 2020-12-02
JP7506606B2 (ja) 2024-06-26
IL276180A (en) 2020-09-30
AU2019211446A1 (en) 2020-09-10
CN112567246A (zh) 2021-03-26
US20230107651A1 (en) 2023-04-06
JP2023118821A (ja) 2023-08-25
US20210041459A1 (en) 2021-02-11
WO2019147960A1 (en) 2019-08-01
JP2021511389A (ja) 2021-05-06
SG11202006677XA (en) 2020-08-28
BR112020015082A2 (pt) 2021-01-05

Similar Documents

Publication Publication Date Title
MX2020007852A (es) Metodos para el tratamiento de la atrofia muscular espinal.
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
MY202410A (en) Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
BR112017025813A2 (pt) método, kit ou composição, micróbio comensal benéfico, método para tratar ou prevenir o câncer e formulação bacteriana
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
EA201400491A1 (ru) Сопровождающая диагностика для терапии с антигиалуроновым агентом и способы ее применения
WO2019014328A3 (en) AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
MY176706A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
BR112017002809A2 (pt) métodos para tratar câncer cervical
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
AU2017245629A1 (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
MX2022001008A (es) Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores.
NZ729773A (en) Biomarkers for disease progression in melanoma
MX2019015324A (es) Instrumento de extraccion comprimible para pretratar una muestra.
MX2016014329A (es) Microbiota ibs y sus usos.
MX2017009998A (es) Biomarcadores para cancer pancreatico.
EA201890868A1 (ru) Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей
TW201614237A (en) Markers for identifying patients responsive to anti-PD-L1 antibody therapy
AU2016250096A8 (en) Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
WO2018064013A8 (en) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
MX2021007951A (es) Ensayo multiplexado y metodos de uso del mismo.
GB2552271A (en) A method for diagnosing lung cancer
PT3289096T (pt) Processo para o prognóstico e/ou diagnóstico de uma doença à base de uma amostra de tecido adiposo